The CDC's ACIP recommended that ROTARIX be routinely given to infants to protect against rotavirus gastroenteritis (RGE). ROTARIX is the only rotavirus vaccine to allow for completion of the rotavirus series by four months of age with just two oral doses. In addition, the ACIP recommended that KINRIX may be given to children 4 to 6 years-old as the fifth dose of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) and the fourth dose of Inactivated Poliovirus (IPV).
KINRIX is the first approved combination vaccine to offer protection against all of these diseases in one shot for eligible 4 to 6 year olds. Children this age may need five or more vaccinations in a single office visit. By combining two vaccinations into one shot, KINRIX can help ease the vaccination process for children, parents and vaccinators. The ACIP also voted to include ROTARIX and KINRIX in the U.S. federal government's Vaccines for Children (VFC) program.
ROTARIX Offers Protection Against the Most Commonly Circulating Rotavirus Types
ROTARIX is indicated for the prevention of rotavirus gastroenteritis
caused by G1 and non-G1 types (G3, G4, and G9) when administered orally as
a two-dose series in infants and children. ROTARIX was developed to mimic
natural infection and to protect against rotavirus gastroenteritis without
regard to serotype. Studies have shown that naturally occurring rotavirus
infection protects against subsequent moderate to severe rotavirus
Copyright©2008 PR Newswire.
All rights reserved